LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

Journal article

Peer reviewed

P Kwo, N Gitlin, R Nahass, D Bernstein, S Rojter, E Schiff, M Davis, P.J Ruane, Z Younes, R Kalmeijer, …

Journal of hepatology, Vol.62, pp.S270-S270

2015-04

Metrics

7 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.125 Hepatitis; 1.125.83 HCV
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
Creators: P Kwo - Indiana University – Purdue University Indianapolis
N Gitlin - Atlanta Gastroenterology Specialists, Atlanta, GA
R Nahass - ID Care, Hillsborough, NJ
D Bernstein - Hofstra University
S Rojter - National Research Institute, Los Angeles, CA
E Schiff - University of Miami
M Davis - Digestive Care
P.J Ruane - Ruane Medical
Z Younes - Gastro One
R Kalmeijer - Janssen
M Peeters - Janssen
O Lenz - Janssen
B Fevery - Janssen
G De La Rosa - Janssen
J Scott - Janssen
R Sinha - Janssen
J Witek - Janssen
Publication Details: Journal of hepatology, Vol.62, pp.S270-S270
Publisher: Elsevier B.V
Academic Unit: Leadership Department; Miller School of Medicine; UMMG Dept of Medicine - Hepatology
Language: English
Resource Type: Journal article
Record Identifier: 991031713824802976